Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Then BK
Wrong board
Time to start posting about conferences and appointing board members.
That’s all they do
Wow - typical Mannkind.
Dilution to the max.
More dilution - here it comes.
Up 1.50
Running big in AH
How high can this go?
Continues to fall. Not looking good
Not sure - looks like someone knows something
What’s the bad news do t see
Xmas and stimulus pmt on its way - thought we would see 3300 today
I hope it’s not and this company is legit.
That PR all but confirms that are probably just a scam penny stock.
Are you kidding me. No wonder warp speed has put on jets in the opposite direction away from vaxart.
That PR is a bunch of BS. Holy Cow that pushed the creative writing on that one.
Do not understand the 3.20 at all.
Just screwed investors today big time with that announcement.
This would have run 5-8 bucks today if that was not announced or set at a better price.
The big ride will probably only happen with another reverse split.
Death to shareholders
Be nice to know why they raised it. Maybe a PR will be out today. They must know something.
Here comes the dive
This probably just another penny scam stock
Tough call this morning
Could crash back down to 7 or move up to 18
Tough call here with no news from company.
Wrong board
Tough call this crash back down to 7 quick after opening or move up quickly to 18
Tough call here
Going to be a nice rally tomorrow or dive on an announcement the loan was not going to happen.
If they know it’s not going through they will have to announce it.
Will loan hold be released?
1:27p ET 12/6/2020 - Dow Jones
Watchdog for U.S. Agency that Brokered Controversial Kodak Deal Finds No Wrongdoing -- 2nd Update
Mentioned: KODK
By Rachael Levy
A government watchdog agency found no wrongdoing in the process that created a now-halted U.S. loan to Eastman Kodak Co. to produce drug ingredients for the Covid-19 response, according to a copy of the assessment reviewed by The Wall Street Journal.
The inspector general of the agency that brokered the deal, the U.S. International Development Finance Corp., provided his assessment last week to Sen. Elizabeth Warren (D., Mass.), who had called for the investigation after the one-time photo giant landed a potential $765 million government loan in July.
In his response, the DFC's inspector general, Anthony Zakel, said he found no evidence that employees of the agency had any conflicts of interest in the plans, nor did he find "any evidence of misconduct on the part of DFC officials."
The review follows a high-profile period for the DFC, which President Trump empowered to support the Covid-19 response under the Defense Production Act. Revamped during the Trump administration, the agency usually focuses on funding projects in the developing world and is run by Adam Boehler, a health-care professional who was formerly a roommate of the president's son-in-law, Jared Kushner.
The Kodak plan came together quickly -- in "Trump time," as White House adviser Peter Navarro, who spearheaded the deal, has said.
Under the plan, Kodak would produce ingredients for some generic drugs, including the antimalarial drug hydroxychloroquine, which Mr. Trump has promoted as a treatment for the coronavirus. Researchers have said the drug has no benefit as an early outpatient treatment.
But the loan plan quickly unraveled. The Securities and Exchange Commission began an investigation into how Kodak disclosed the loan. Democrat-led congressional committees announced probes and the DFC put the loan on indefinite hold.
Under government pressure, Kodak had rushed out the announcement before the loan was finalized, the Journal earlier reported. The company bungled its release to local media, sending Kodak's stock on a roller coaster. Senior administration officials have denied the DFC pressured Kodak to announce the deal.
In his assessment, the DFC inspector general said his office is planning future audits of the agency's projects under the Defense Production Act, including how the agency announces "market-sensitive" transactions involving publicly traded companies.
When the plan was announced, Kodak still had many steps to complete in its loan process with the DFC, including whether the plan met the agency's minimum-eligibility requirements, the inspector general said in his review.
He found it reasonable for the DFC to consider Kodak for the loan, noting other companies' recent pivots to Covid-19 supply-chain manufacturing and Kodak's experience providing materials to the pharmaceutical industry.
"The record is abundantly clear and the independent IG review confirms that DFC followed its standard process, under its standard timeline, driven by career finance professionals," a DFC spokesman said.
A representative for Kodak declined to comment.
An aide for Sen. Warren said the inspector general's assessment didn't review whether there were contacts between the White House and other political appointees about the deal. The aide said the review also didn't determine whether the DFC's process was adequate to prevent waste or abuse of taxpayer funds.
"We focused our review on issues within DFC [office of the inspector general's] purview and authority," Mr. Zakel said. "We did not review conduct by Kodak or non-DFC personnel."
Kodak conducted its own investigation. That review found the company didn't break any laws in connection with the disclosure of the loan.
Kodak's review did find several governance issues at play, however. One issue was a gift of Kodak stock made by Kodak board member George Karfunkel on the same day the stock's price peaked, after the government's announcement. Mr. Karfunkel donated the stock, worth $116 million, to a religious charity he started.
Kodak has admitted to other issues since then. Last month, the company said five former executives were able to collect millions of dollars by selling stock options they didn't own due to weak internal controls that failed to prevent unauthorized issuance of the company's stock. Kodak has said it would try to recover about $3.9 million from the ex-employees for the fair value of the shares at the time of the sale and about $3 million from the withholding of taxes on behalf of the ex-employees.
At a Journal conference in October, Kodak's Chief Executive Jim Continenza defended his company's handling of the loan plans and said that Kodak would move ahead in making drug ingredients regardless of whether it receives government assistance.
Meanwhile, the DFC has announced a new loan in its coronavirus response. Last month, the agency said it approved a $590 million loan to ApiJect Systems Corp. to produce prefilled injectors for vaccines. The Food and Drug Administration hasn't approved the devices for distribution though the company has been in discussions with the FDA, according to an ApiJect spokesman. The FDA didn't respond to a request for comment.
Back in mid oct they announced first human dosage.
Whatever happen to those results?
Article quote
He said the company anticipates receiving the first clinical data in the next few weeks.
Def been a few weeks.
A lot of news on hamsters but nothing on humans.
Did I miss this news?
Another stellar day for Vaxart
Cannot even hold 7 bucks.
Very disappointing stock.
This company is more about lining their pockets than increasing shareholder value.
Primate study?
Long long over due. Not a peep.
Pretty much puts the final nail in the Kodak coffin
News out at 6:00 pm.
Executives sold shares they didn’t own.
Under investigation and 90% effective vaccine to be available soon.
Unless they come out with huge primate study news and huge trial news this is headed to zero.
Zero chance of warp speed monies. This may have been one big scam. Who knows but sure looking like it now.
One a penny always a penny
Hate to say it but this company is all but done.
To many big players getting close and no updates to even think Vaxart is close
I see no news - why is this moving ?
This is falling fast in AH.
Great numbers - what am I missing.
Bankruptcy on its way?